Figure 4. In vivo anti-tumour effects of CA-[Glc].
In the mouse therapeutic model of pre-established HCT116 tumours, CA-[Glc] complex containing 50 mg glucose, CA, Glc (50 mg glucose), or saline was intravenously injected through the tail vein, when the tumour volume reached approximately 80 mm3, three times per week for 2 weeks. On day 16, the tumour volume of mice treated with CA-[Glc] was significantly smaller than in mice treated with CA (P = 0.0282), Glc (P = 0.0282), or saline (P = 0.0072). (n = 19 for saline, n = 8 for CA or Glc, n = 6 tumours for CA-[Glc], Steel-Dwass All Pairs Test).